Inhibrx Biosciences (INBX) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inhibrx Biosciences (INBX) has outperformed Taysha Gene Therapies (TSHA) over the past year, gaining 176.0% versus a loss of 12.5%. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | TSHA |
|---|---|---|
| Share price | $92.76 | $4.43 |
| Market cap | $1.37B | $1.44B |
| 1-day change | -0.64% | 0.00% |
| YTD return | +17.42% | -19.45% |
| 1-year return | +175.99% | -12.45% |
| 5-year return | — | -75.22% |
| EPS (TTM) | $-8.88 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.77M |
| Revenue growth (YoY) | — | +17.28% |
| Net income (latest FY) | — | $-109.00M |
| Operating margin | — | -1130.65% |
| Net margin | — | -1115.27% |
| 52-week high | $155.29 | $7.30 |
| 52-week low | $28.16 | $3.69 |
| Distance from 52-week high | -40.27% | -39.32% |
| Analyst consensus | none | none |
| Avg. price target upside | +187.48% | +193.45% |
| Average volume | 284.58K | 3.28M |
| Shares outstanding | 14.72M | 325.83M |
| Employees | 109 | 99 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INBX has outperformed TSHA by 188.4 percentage points over the past year.
- The two companies sit in different sectors: Inhibrx Biosciences in Health Care and Taysha Gene Therapies in Healthcare.
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
INBX vs TSHA FAQ
Which is bigger, Inhibrx Biosciences or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.37B for Inhibrx Biosciences (INBX).
Which stock has performed better over the past year, INBX or TSHA?
INBX returned +175.99% over the past 12 months, compared with -12.45% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Inhibrx Biosciences and Taysha Gene Therapies in the same industry?
No. Inhibrx Biosciences is in the Health Care sector, while Taysha Gene Therapies is in Healthcare.